At a glance
ClinicalIndex Comparison Record- ✓Advanced and/or metastatic cancer refractory to standard therapy or for which gemcitabine would be appropriate (Phase 1b)
- ✓Histological or cytological diagnosis of pancreatic adenocarcinoma that is locally advanced (Stage II, III) or metastatic (Stage IV) and not amenable to resection with curative intent (Phase 2)
- ✓Measurable or non-measurable disease per RECIST
- ✓ECOG performance status ≤2
- ✕Moderate or severe cardiac disease including myocardial infarction within 6 months, unstable angina, NYHA Class III/IV CHF, or uncontrolled hypertension
- ✕Major cardiac abnormalities by echocardiography including moderate/severe valve dysfunction or LVEF <50%
- ✕Predisposing conditions for aortic aneurysms or aortic stress (e.g., family history of aneurysms, Marfan syndrome, bicuspid aortic valve, imaging evidence of large vessel damage)
- ✕Unable to swallow tablets or capsules
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
2 articles- Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026GlobeNewswire Biotech·2026-06-08press release
- #ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearEndpoints News·2026-06-06
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)
In Brief
A Phase 2 clinical trial evaluating Galunisertib, Gemcitabine, and 1 other intervention for Neoplasms and 2 related conditions. Completed, enrolled 170 participants across 24 sites in 6 countries.
Detailed Summary
Phase 1b: To determine the safe and tolerable dose of galunisertib in combination with gemcitabine in patients with solid malignancy Phase 2a: To compare the overall survival (OS) of patients with Stage II to IV unresectable pancreatic cancer when treated with a combination of galunisertib and gemcitabine with that of gemcitabine plus placebo.
Study Details
Timeline
Interventions
Administered orally
Administered intravenously
Administered orally